Format
Sort by

Send to

Choose Destination

Selected items

Items: 3

1.

Four novel RET germline variants in exons 8 and 11 display an oncogenic potential in vitro.

Muzza M, Cordella D, Bombled J, Bressac-de Paillerets B, Guizzardi F, Francis Z, Beck-Peccoz P, Schlumberger M, Persani L, Fugazzola L.

Eur J Endocrinol. 2010 Apr;162(4):771-7. doi: 10.1530/EJE-09-0929. Epub 2010 Jan 26.

PMID:
20103606
2.

Nationwide French Study of RET Variants Detected from 2003 to 2013 Suggests a Possible Influence of Polymorphisms as Modifiers.

Lebeault M, Pinson S, Guillaud-Bataille M, Gimenez-Roqueplo AP, Carrie A, Barbu V, Pigny P, Bezieau S, Rey JM, Delvincourt C, Giraud S, Veyrat-Durebex C, Saulnier P, Bouzamondo N, Chabbert M, Blin J, Mohamed A, Romanet P, Borson-Chazot F, Rohmer V, Barlier A, Mirebeau-Prunier D.

Thyroid. 2017 Dec;27(12):1511-1522. doi: 10.1089/thy.2016.0399. Epub 2017 Nov 3.

PMID:
28946813
3.

In vitro transforming potential, intracellular signaling properties, and sensitivity to a kinase inhibitor (sorafenib) of RET proto-oncogene variants Glu511Lys, Ser649Leu, and Arg886Trp.

Prazeres H, Couto JP, Rodrigues F, Vinagre J, Torres J, Trovisco V, Martins TC, Sobrinho-Simões M, Soares P.

Endocr Relat Cancer. 2011 Jul 1;18(4):401-12. doi: 10.1530/ERC-10-0258. Print 2011 Aug. Erratum in: Endocr Relat Cancer. 2016 Dec;23 (12 ):X1.

PMID:
21551259

Supplemental Content

Support Center